Coverage: The Meridian legal market record (editorial).
The licensee is an Egyptian manufacturer taking manufacturing rights to a patented HIV medicine; the African nexus is party-domicile and manufacturing-location based.
| Record ID | TX-AFR-2024-0001 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Non-exclusive licence, Technology transfer, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2024-12 (month precision) |
| Sector | Life sciences · Pharmaceuticals – HIV |
| African markets | Egypt |
| Licensed territory | The release describes a voluntary licence to manufacture and supply generic lenacapavir; the territory list is not reproduced in the material reviewed. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- EVA Pharma (Egypt): licensee, manufacturer
- Gilead Sciences (United States): licensor
Key terms
- Interest: non-exclusive licence; Exclusivity: non-exclusive; Territorial scope: Not stated in material reviewed
- Financial terms as reported: “non-exclusive, royalty-free voluntary licensing agreement”
Sources
- EVA Pharma announces non-exclusive, royalty-free voluntary licensing agreement with Gilead for generic lenacapavir, EVA Pharma (via APO Group Africa Newsroom), 2024-12-17
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


